Subject: TRTC Partner News: NTRI Completes Phase I Development of Therapeutic CBD Product Line

SCV Client Spotlight
TRTC Partner News: NTRI Completes Phase I Development of Therapeutic CBD Product Line
Hot Stock to WatchHot Stock to Watch

Company: Terra Tech Corp (OTCQB: TRTC)


Price: 0.3949

Change (%): + 0.0039 (1.00)

Volume: 742,488
TRTC Chart

Inergetics Completes Phase I Development of its Therapeutic CBD Line of Products

The New York Times calls for the national legalization of cannabis accelerating validation of CBD

NEWARK, N.J., July 29, 2014 /PRNewswire/ - Inergetics, Inc. (OTCBB: NRTI), a leading developer of nutritional supplements, today announced the successful completion of its first phase towards the formulation of its proprietary line of natural cannabidiol CBD-based nutritional supplements it is developing in partnership with Terra Tech Corp (OCTBB: TRTC). Research shows that cannabinoids have medical application for a range of conditions as varied as epilepsy, glaucoma, osteoporosis, anorexia, Alzheimer’s disease and pain treatment.

Following the recent success of the CBD Medical Advisory Board meeting led by Inergetics’ Chief Science Officer, Carl Germano, RD, CNS, CDN, Inergetics has successfully procured targeted cannabinoids from industrial hemp, cannabis and other unique dietary sources.

“This is a critical milestone for us in our quest to enter the marketplace as the gold standard of cannabinoid supplements,” says Germano. “Innovation in cannabinoid extraction from food sources other than cannabis and hemp as well as leading technology to enhance bioavailability was our number one goal in this important phase of the initiative and we achieved it.”

“Our considerable momentum completing Phase I of our CBD product development is timely with growing validation in the marketplace as a major national news organization like The New York Times takes a position as it did this Sunday, July 27th in its editorial section calling for the national legalization of cannabis,” said Inergetics CEO Mike James. “In addition, it is important to note that the medical applications of cannabis and CBD are varied with the greatest opportunity in the broader consumer marketplace. Our progress is significant and puts Inergetics on the leading edge of this business.”

Inergetics’ CBD-based supplements are expected to be distributed via medicinal marijuana dispensaries in 2015.

Continue Reading

Like Us on FacebookFollow Us on Twitter

SmallCapVoice (SCV) is an electronic publication. Information sources for our profiles include, but are not limited to, online research, member suggestions, magazines, newspapers, analyst suggestions, information provided by the profiled company, press releases and similar sources. This communication is not an offer to sell or a recommendation that you buy or sell any security. SCV holds no securities licenses and is not qualified to provide investment advice. We are compensated for these advertisements by the profiled companies. You should not use this newsletter as the sole basis for any investment decision. While all investments involve risk, microcap stocks are among the most risky. Many microcap companies have no proven track record. You should only invest in microcap companies if you can afford to lose your entire investment. You should consult a qualified, licensed financial advisor or stock broker before making any decisions to invest in the securities of any company that is described in these profiles. These profiles are paid advertisements. Although we have a reasonable belief that the information in each profile is accurate, we cannot guarantee that the information is accurate. It is important for you to verify all information by your own independent research. You are receiving this message because you have agreed to receive emails from You may opt out of our distribution list at any time by clicking on the “unsubscribe” link below. Link to full disclosure about compensation paid to, Inc. by companies featured on our website or in our e-mail communications.

About Penny Stocks